Company intelligence / Profile preview

MindChip

New York, New York, United Statesmindchip.ee ↗

Ownership: Private
Development stage: Commercial

Overview

MindMed has completed multiple phase 1 and phase 2 studies with positive topline data. Its lead asset, MM120 (lysergide/LSD), demonstrated statistically significant improvements in GAD scores and has advanced to Phase 3 trials. Additional programs include MM402 ((R)-MDMA) for autism spectrum disorder now in Phase 1. The company continues to expand its pipeline targeting brain health disorders with both perceptual and non-perceptual psychedelic compounds[3][5][6].

Therapeutic areas: Psychiatry
Modalities: Small moleculePsychedelic drugPsychoplastogen (novel class)Entactogen
Industry: Biotech

Beyond the preview

Go deeper on MindChip.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MindChip.

Explore the full profile